Alcon IOLs, Bausch & Lomb Refractive Surgery Generate Q1 Growth
This article was originally published in The Gray Sheet
Executive Summary
Alcon expects its AcrySof Natural intraocular lenses to continue to drive surgical sales, having accounted for 27% of U.S. IOL sales at the end of the first quarter
You may also be interested in...
Alcon Focuses On Non-Medicare Market For AcrySof ReStor Intraocular Lens
Alcon initially will target the 10%-20% of U.S. patients that undergo an intraocular lens procedure outside of the Medicare system for its newly-approved AcrySof ReStor accommodating IOL
Alcon Focuses On Non-Medicare Market For AcrySof ReStor Intraocular Lens
Alcon initially will target the 10%-20% of U.S. patients that undergo an intraocular lens procedure outside of the Medicare system for its newly-approved AcrySof ReStor accommodating IOL
CrystaLens Accommodating IOL First To Market; Firm Eyes Expanded Labeling
Eyeonics, Inc. will file a supplemental PMA for its CrystaLens AT-45 accommodating posterior chamber intraocular lens to broaden the treatment range beyond 1.0 diopter